Attestation committee
Accreditation committee
Expert committee
Dispositions, instructions
Normative acts
Scientific councils
Scientific advisers
Doctoral students
Postdoctoral students
CNAA logo

 română | русский | english

CNAA / Theses / 2019 / May /

Immunological and immunophenotypic features of non - Hodgkin’s lymphomas

Author: Nicorici Aliona
Degree:doctor of medicine
Speciality: 14.00.14 - Oncology and Radiotherapy
Scientific adviser: Valentina Stratan
doctor, associate professor (docent), Chisinau Pedagogical State University "Ion Creanga"
Scientific consultant: Ion Corcimaru
doctor habilitat, professor, Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova
Institution: Public Medical Sanitary Intitution Institute of Oncology


The thesis was presented on the 30 May, 2019
Approved by NCAA on the 9 July, 2019


Adobe PDF document16.00 Mb / in romanian


CZU 616.411- 006.441-07

Adobe PDF document 16.00 Mb / in romanian
131 pages


Non-Hodgkin's lymphoma, immunophenotyping, monoclonal antibodies, immunoglobulins, polymicherapy, humoral immune response, personalized treatment, prognosis, malignancy


Structure of the thesis: The thesis is exposed on 135 pages including: introduction, 4 chapters, synthesis of the results obtained, general conclusions and practical recommendations, bibliography from 108 sources, 5 annexes, 12 figures, 18 tables, 10 photographs. The results obtained are published in 11 scientific papers.

Field of study: oncology, medicine, laboratory.

Study aim: We aim to study and analyze dynamically the immunobiological and immunophenotypic parameters in the treatment of NHL patients in the scientific argumentation and the demonstrative capitalization of the predictive factors in the improvement of the longterm survival rate and the recognition of immunological and immunophenotypic remissions in choosing customized treatment methods.

Objectives of the thesis: 1. Evaluation and analysis of the indices: immunobiological and immunophenotypic at the stages of diagnosis, treatment and remission of the patients with NHL; 2. Phenotypic malignancy analysis and fenotipice differentiation of B-cell and T-cell LNH by Ac-monoclonal prism (AcMo); 3. Identifying factor determining the predictive characteristics in accordance with prescribed and recom mended training and deficiencies; 4. Elaboration, patenting, certification, implementation of new diagnostic methods and motitorisation in the target treatment of LNH in order to maintain clinical, immunophenotypic and immunological remissions

Research methodology: The study - retrospective with a prospective component. Research, being ocohematological patients with primary morphological diagnosis of NHL, determined by immunohistochemistry biopsy. The direct and indirect observation models were used in the research of peripherally anti-aggregated blood with ethylenediaminetetraacetic acid at the onset of the disease, following the application of the specific therapy with intervals after 3 and 6 cycles of PCHT, with the assessment of humoral homeostasis indices, the estimation of the lymphoma phenotype in percentages of this by labeling Ac - monoclonal lymphocytes by the indirect method, comparing them for a deductive analysis.

Novelty and scientific originality:Analysis of immunological and immunophenotypic data depending on the treatment applied and the number of PCHT treatments used, will provide the opportunity to optimize the therapeutic protocols applied with the use of new elements. Recurrence of recurrences requires us to seek new PCHT treatment regimens with the inclusion of specific drugs that would ensure the subsequent development of a target treatment. The solved scientific problem: AcMo features are particularly important for the success of therapy. The use of chimeric or human AcMo (which has a higher half-life compared to murine) will diminish immune rejection, facilitating the effectiveness of applied clinical action. Theoretical significance and applicative value of the work: In order to detect early and late recurrences, existing or emerging side effects and the occurrence of malignancy, it is necessary to determine the percentages of lymphoma phenotype and peripheral Ig characteristics to assess the immune status of oncohematological patients in order to increase the survival rate and better use of the quality of life.